Viking Therapeutics to Present at Stifel Healthcare Conference 2020
Viking Therapeutics (NASDAQ: VKTX) is set to present at the Stifel Healthcare Conference 2020, with CEO Brian Lian, Ph.D., delivering insights on the company's innovative therapies for metabolic and endocrine disorders. The virtual event will occur from November 16-18, 2020, with Viking's presentation scheduled for 11:40 a.m. PST on November 17, 2020. Investors can access the live webcast on Viking's website, where a replay will also be available post-conference. Viking is advancing its clinical programs, which include VK2809 and VK0214, targeting significant health issues.
- None.
- None.
SAN DIEGO, Nov. 10, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the Stifel Healthcare Conference 2020. The conference, which will take place November 16-18, 2020, is being conducted with a virtual format.
Details for this presentation are as follows:
- Stifel Healthcare Conference 2020 – webcast available
Time/Date: 11:40 a.m. Pacific on Tuesday, November 17, 2020
A live webcast of the Stifel presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts. Additionally, a replay of the webcast will be available on the Viking website following the conference.
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1 first-in-human clinical trial. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. Follow Viking on Twitter @Viking_VKTX.
View original content to download multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-to-present-at-stifel-healthcare-conference-2020-301170137.html
SOURCE Viking Therapeutics, Inc.
FAQ
What is Viking Therapeutics' stock symbol?
When will Viking Therapeutics present at the Stifel Healthcare Conference?
How can I access Viking Therapeutics' presentation at the conference?
What are the key programs being developed by Viking Therapeutics?
What are Viking Therapeutics' recent clinical studies?
